Vasundhara Rasayans Limited has confirmed full compliance with the Securities and Exchange Board of India (SEBI) regulations for the financial year ended March 31, 2026. The company submitted its Annual Secretarial Compliance Report to BSE Limited on May 30, 2026, detailing its adherence to listing obligations and disclosure requirements.

The report, certified by Practicing Company Secretary Rakhi Agarwal, examined the company's compliance with various regulations including the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and the SEBI (Prohibition of Insider Trading) Regulations, 2015. The review confirmed that the listed entity complied with all provisions of the regulations and circulars issued thereunder during the review period.

A detailed review of specific compliance parameters revealed that the company has no subsidiaries and no actions were taken against it, its promoters, or directors by SEBI or stock exchanges. The report also noted that all related party transactions were approved by the Audit Committee.

The certification process relied on documents and records made available by the management, filings submitted to stock exchanges, and the company's website. The report clarified that it is neither an audit nor an expression of opinion on the financial records of the company.

Vasundhara Rasayans reported a 36.3% rise in net profit to ₹578.91 lakh for the financial year ended March 31, 2026, compared to ₹424.63 lakh in the prior year. Revenue from operations for FY26 increased to ₹3,572.31 lakh from ₹3,399.01 lakh in FY25. The company’s statutory auditors, M/s. Mamta Jain & Associates, issued an unmodified opinion on the audited financial results.

For the quarter ended March 31, 2026, the company recorded a net profit of ₹247.82 lakh, a significant increase from ₹44.63 lakh in the corresponding quarter of the previous year. Total income for the quarter stood at ₹1,258.38 lakh, up from ₹858.80 lakh in Q4FY25. Earnings per share (EPS) for the full year improved to ₹18.22 from ₹13.36 in the previous year.

The Board of Directors, at its meeting held on May 28, 2026, approved the audited standalone financial results. Based on the recommendation of the Nomination and Remuneration Committee, the Board appointed Shri Ravi Jain as an Additional Director (Non-Executive Independent Director) effective May 28, 2026, for a term of five years subject to shareholder approval. Mr. Ravi Jain is a Graduate with over 10 years of experience in marketing and business development across consumer goods. He has led strategic marketing, brand-building, and customer-acquisition initiatives, and is not related to any other Director on the Board.

Mr. Pradeep Kumar Jain retired as a Non-Executive Independent Director upon completing his second term of five consecutive years. In a strategic move, the Board approved entering into a Memorandum of Understanding cum Loan-Lease Agreement with PandJ Cretechem Private Limited, the holding company. This agreement establishes a manufacturing arrangement for Active Pharmaceutical Ingredients (APIs) at the holding company's facility in Dahej, Gujarat. The Audit Committee had previously approved and recommended this transaction on May 28, 2026.

The Board also reconstituted the Audit Committee, Nomination and Remuneration Committee, and Stakeholders Relationship Committee, appointing Mr. Manish Jain as the chairperson of each committee effective May 29, 2026.

Financial Results for FY26